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AbstrACt
Introduction Osteoporosis is a systemic skeletal disease 
that is characterised by reduced bone strength and 
increased fracture risk. Osteoporosis-related fractures 
impose enormous disease and economic burden to 
the society. Although many treatments and health 
interventions are proven effective to prevent fractures, 
health economic evaluation adds evidence to their 
economic merits. Computer simulation modelling is a 
useful approach to extrapolate clinical and economic 
outcomes from clinical trials and it is increasingly used 
in health economic evaluation. Many osteoporosis health 
economic models have been developed in the past 
decades; however, they are limited to academic use and 
there are no publicly accessible health economic models 
of osteoporosis.
Methods and analysis We will develop the Australian 
osteoporosis health economic model based on our 
previously published microsimulation model of 
osteoporosis in the Chinese population. The development 
of the model will follow the recommendations for the 
conduct of economic evaluations in osteoporosis by the 
European Society for Clinical and Economic Aspects of 
Osteoporosis, Osteoarthritis and Musculoskeletal Diseases 
and the US branch of the International Osteoporosis 
Foundation. The model will be a state-transition semi-
Markov model with memory. Clinical parameters in 
the model will be mainly obtained from the Dubbo 
Osteoporosis Epidemiology Study and the health economic 
parameters will be collected from the Australian arm of 
the International Costs and Utilities Related to Osteoporotic 
Fractures Study. Model transparency and validates will be 
tested using the recommendations from Good Research 
Practices in Modelling Task Forces. The model will be used 
in economic evaluations of osteoporosis interventions 
including pharmaceutical treatments and primary care 
interventions. A user-friendly graphical user interface 
will be developed, which will connect the user to the 
calculation engine and the results will be generated. The 
user interface will facilitate the use of our model by people 
in different sectors.
Ethics and dissemination No ethical approval is 
needed for this study. Results of the model validation and 
future economic evaluation studies will be submitted to 
journals. The user interface of the health economic model 
will be publicly available online accompanied with a user 
manual.
IntroduCtIon
Osteoporosis is a common disease that is 
usually silent until a fracture occurs. Frac-
ture is a global health concern particularly 
in women. Australian women aged 60 years 
were estimated to have a residual lifetime 
fracture risk of 44% and the risk for Chinese 
women was approximately 33%.1 2 Despite a 
lower residual lifetime risk of having a frac-
ture in men, the overall mortality HR in men 
after a fracture was higher than women.3 
For those who survived fractures, quality of 
life (QoL) deteriorated dramatically up to 
6 months after fracture and the loss of QoL 
persisted in the remaining lifetime.4 With 
an accelerated ageing global population, 
the number of fractures will increase in the 
coming decades.5 6
Bone strength is mainly reflected by bone 
mineral density (BMD). Individuals with 
reduced BMD are at the greatest risk of 
osteoporotic fracture. The assessment of 
fracture risk is largely based on clinical risk 
factors with and without BMD.7 With the 
strengths and limitations of this study
 ► We will develop a state-transition microsimulation 
for health economic evaluation of osteoporosis 
interventions.
 ► The model will be based on the Australian setting 
and will be adapted and adaptable to other settings.
 ► The model will be publicly available with a web in-
terface to allow access for future users to evaluate 
new osteoporosis interventions of interest in their 
own settings.
 ► The model will be developed following the consensus 
statement endorsed by the Scientific Advisory Board 
of Economic Aspects of Osteoporosis, Osteoarthritis 
and Musculoskeletal Diseases, the Committee of 
Scientific Advisors and the Committee of National 
Societies of International Osteoporosis Foundation, 
the US National Osteoporosis Foundation and 
Osteoporosis Canada.
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predicted fracture risk, treatment decisions can be made 
following primary or secondary fracture prevention.8 9
Numerous therapeutic regimes, including pharmaceu-
tical interventions, have been developed to treat osteopo-
rotic patients by improving their BMD. While treatment 
of osteoporosis has proven effective in preventing future 
fractures, the associated cost must be considered against 
the costs of not preventing fractures. In 2011/2012, the 
Australian government spent over 179 million Austra-
lian dollars in pharmaceuticals for osteoporosis manage-
ment.10 Similar costs of osteoporosis medications have 
been noted elsewhere.6 11 12 With a range of osteoporosis 
treatments available in the community, some govern-
ments employ health economic evaluation in treatment 
reimbursement policy making, such as the Pharmaceu-
tical Benefits Advisory Committee (PBAC) in Australia 
and the National Institute for Health and Care Excellence 
(NICE) in the UK. These government agencies conduct 
health economic evaluations of osteoporosis treatments 
to select those that represent good value for money.
Health economic evaluation of osteoporosis interven-
tions is commonly conducted using disease modelling 
approaches,13 such as Markov cohort models and indi-
vidual-level state-transition models.14–16 Health economic 
modelling using different sources of information is able 
to capture long-term cost and health benefits of osteo-
porosis interventions. Health economic analyses of oste-
oporosis interventions may be limited due to the validity, 
transparency and accessibility of health economic models 
that are used in the analyses. Making health economic 
models transparent via thorough documentation and 
making them available for public use are potential solu-
tions to minimise these limitations; moreover, these solu-
tions provide opportunities to update existing models with 
newly available epidemiological and health economic data 
as they become available.17 To date, there is no publicly 
accessible health economic model of osteoporosis.
objECtIvE
We aim to develop a publicly available health economic 
model to evaluate the cost-effectiveness of osteoporosis 
interventions. The model will be based on the Austra-
lian setting and will be adapted and adaptable to other 
settings. Moreover, we will develop a web interface to 
allow access for future users to evaluate new osteoporosis 
interventions of interest in their own settings.
MEthods And dEsIgn
Model structure and parameters
We have published a microsimulation model of osteo-
porosis in the Chinese population and will develop the 
Australian model using the existing model structure.18 
The model will incorporate Australian fracture risk 
equations for estimating absolute risk of osteoporosis 
fractures based on patients’ characteristics (eg, age, sex, 
family history, BMD, history of fractures and falls as well 
as comorbidities), and time-varying factors such as expo-
sure to primary and/or secondary fracture prevention 
therapy and patients’ accumulated history of fractures. 
These equations will form the basis of the simulation 
model for estimating outcomes for Australian patients 
with osteoporosis.
The development of our osteoporosis health economic 
model will follow the recently published modelling 
guideline in osteoporosis.19 Simulations will be based 
on a state-transition individual patient simulation model 
(figure 1). Simulated patients in the model are either 
alive or dead based on annual transitions. Outcomes will 
be analysed over patients’ lifetimes but time horizons may 
be varied according to the study of interest. Simulated 
patients will transit in the model until they are absorbed 
in the ‘death’ state.
Fragility facture is a key outcome of osteoporosis and 
can occur in hip (proximal femur), vertebrae (spine), 
wrist (distal radius) and other non-hip non-vertebral sites 
such as humerus, pelvis, ribs and shoulder. Simulated 
patients can have multiple fractures at different fracture 
sites. Fracture probabilities will be simulated from one of 
three risk engines. First, for countries that report fracture 
incidence rates, fracture probabilities will be calculated 
from incidence rates using the following equation:





where p is the probability and r is the annual fracture 
incidence rate by sex, fracture site and BMD level. In the 
model for the Australian population, annual fracture 
incidence rates by sex, fracture site and BMD level will 
be obtained from the Dubbo Osteoporosis Epidemiology 
Study.20 For countries without reported fracture incidence 
rates, users will be able to choose the formula for calcu-
lation of annual fracture probabilities. Ten-year risk for 
hip and all fragility fractures are predicted by the FRAX 
or Garvan Fracture Risk Calculator (GARVAN-FRC).21–24 
The annual probability of having a fracture will be calcu-
lated as:
Figure 1 Structure of the osteoporosis state-transition 
model. Simulated patients transit in the model following the 
arrow direction. Simulation is concluded when all simulated 
patients transit to the ‘death’ state. Reprinted by permission 
from Springer Nature Customer Service Centre GmbH: 
Springer Nature.18














where P is the cumulative risk of having a fracture over 
a period of t years. For example, for a given set of clin-
ical risk factors, a group of patients is estimated to have 
a 5% 10-year probability of having a hip fracture. In this 
scenario, the annual probability of having a hip fracture 
is calculated as 0.51%.
Simulated patients could stay without any fracture for 
the entire life (represented as ‘no history of fracture’), 
sustain a fracture (represented as ‘fractured’), stay in 
postfracture state (represented as ‘postfracture’) or 
sustain another fracture (represented as ‘fractured’). In 
the case of death, Australian life tables combined with 
fracture site-specific relative risks adjusted by time since 
fracture will be used to calculate the probability of death 
during the course of the simulation.3
The model will primarily take the societal perspective, 
which is a broader perspective accounting for all stake-
holders. In the Australian model, we will use data from 
the Australian arm of the International Costs and Utilities 
Related to Osteoporotic Fractures Study (AusICUROS) 
to calculate the costs of direct health and non-health-
care utilisation.10 Specifically, direct healthcare utilisation 
included hospitalisation, ambulance, imaging, medical 
services, pharmaceuticals and supplements, non-ad-
mitted, subacute/rehabilitation and community-based 
services including GP and physiotherapy services. Direct 
non-healthcare utilisation included residential care, meals 
on wheels and other community services.10 Relevant unit 
costs of the above healthcare utilisation will be taken from 
Pharmaceutical Benefit Scheme (PBS), Medical Benefit 
Scheme (MBS) and other government reporting system 
such as the Australian-refined diagnosis-related groups 
(AR-DRGs). In addition, we will include indirect costs of 
productivity loss. While societal perspective will be used 
primarily, the cost data will be categorised to be adapted 
for a different perspective for future use. For example, 
when evaluating the cost-effectiveness of an osteoporosis 
medication for listing on the PBS, only costs borne by the 
Australian government will be included.
While the model can estimate the life expectancy, it will 
primarily use quality-adjusted life years (QALYs) to quan-
tify health outcomes, since this is the most commonly 
used metric in health economic evaluations. The QALY, 
which adjusts life expectancy by the degree of morbidity, 
is usually measured on a health state utility (HSU) scale 
where zero represents death and one represents full 
health in each year of life. HSUs for each level of disease 
severity will be incorporated from the AusICUROS and 
an international meta-analysis of HSUV changes before 
and after osteoporosis-related fractures.10 25
The overview of the osteoporosis model algorithm is 
illustrated in figure 2.
Microsimulation
The Markov model is commonly used in chronic disease 
modelling to facilitate the fact that patients can transit to 
disease states repetitively during simulation. However, the 
use of Markov modelling is limited to the Markov assump-
tion, which relates to the fact that the future transitions 
are not dependent on previous states.26 In osteoporosis 
epidemiology, patients’ characteristics play an important 
role in transition between disease states. For example, the 
relative risk of having a subsequent fracture for patients 
Figure 2 Overview of osteoporosis model algorithm. QALYs, quality-adjusted life years.
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with a prior fracture was higher and varied by sex, frac-
ture site and BMD level.27 Likewise, mortality was also 
higher after fracture.3 Therefore, we will use an individu-
al-level state-transition model to incorporate the memory 
of events occurring for simulated patients in the model. 
Tracker variables will be used to record events of interest 
during simulation. In our model, we will define the 
following tracker variables to represent the heterogeneity 
of simulated patients: ‘site of each fracture’, ‘number of 
fracture by fracture site’, ‘time of the first fracture’, ‘time 
since the last fracture’ and ‘time after treatment onset’.
Management with uncertainties and reporting uncertain 
analyses
Four types of uncertainties are commonly considered in 
health economic modelling studies, namely stochastic 
uncertainty, parameter uncertainty, heterogeneity and 
structural uncertainty.28 These uncertainities will be dealt 
with during the development of the model and analyses. 
For stochastic uncertainty, sufficient number of first-order 
Monte Carlo simulations will be conducted. For param-
eter uncertainties, CI of parameters along with point esti-
mates will be included in the model. For instance, gamma 
or log normal distribution for cost data, log normal distri-
bution for relative risks or hazard ratios will be used.29 
Both deterministic and probabilistic sensitivity analyses 
will be conducted to report uncertainties. One-way sensi-
tivity analysis will be performed to evaluate how results 
change by changing the value of individual parameters 
and the results will be presented in tornado diagrams. 
Probabilistic sensitivity analysis (PSA) will be conducted 
by simultaneous sampling of all parameters that are 
defined by distributions. Cost-effectiveness acceptability 
curves (CEAC) and distribution of net monetary or net 
health benefits will be presented to illustrate the cost-ef-
fectiveness decisions given a range of willingness-to-pay 
(WTP) thresholds. Handling uncertainties and reporting 
uncertainty analyses will be conducted in line with the 
Good Research Practices in Modelling Task Force-6.28
Model transparency and validation
Cost-effectiveness of health interventions from modelling 
studies informs policy decision makers when they priori-
tise funding for scarce healthcare resources. Therefore, 
the validity and transparency of a health economic model 
are keys in assisting policy decision making. Transpar-
ency of health economic models is subject to how well 
the model is documented including its structure, param-
eters, equations and key assumptions used in the model. 
Validity refers to how well the model represents the real 
world.30 To ensure our model will be developed following 
recommendations from the Good Research Practices in 
Modelling Task Force-7,30 we will make the non-technical 
documentation available following the example of the 
previous work in diabetes from our team.31 There are 
five aspects of validity, namely face validity, internal and 
external validities, cross validity and predictive validity.30 
In our study, we will primarily deal with face, internal and 
external validities of our osteoporosis model.
For face validity, the clinicians in our team (JAE, TW, 
JRC and AJP) will evaluate whether the model presents 
the osteoporosis clinical pathway and the current osteo-
porosis management algorithms in Australia. For internal 
and external validity, we will conduct goodness-of-fit anal-
yses on the model results against values used in developing 
the model (ie, internal validity) and that from literature 
(external validity). In particular, we will compare the 
following values: annual fracture rates by age and sex; life 
expectancies by age and sex; residual lifetime fracture 
risks by age, sex and BMD level. Goodness-of-fit analysis 
will be conducted using linear regression. The slope of 
the regression line along with the R-squared of the regres-
sion line and the root mean square error (RMSE) will be 
used to assess the goodness-of-fit of the model predictions 
and that from the literature.32 In addition, the Bland-Al-
tman statistics will be reported to evaluate the agreement 
between model results and real-world observed results.33
Patient and public involvement
Patients and public will not be involved in this study.
APPlICAtIon of thE ModEl
The first focus of the model application will be to quan-
tify the cost-effectiveness of all first-line osteoporosis 
secondary prevention fracture medications currently 
reimbursed by the PBS in order to identify the most cost-ef-
fective medications and to further identify currently reim-
bursed medications that are not cost-effective indicating 
the need for disinvestment in these medications.34The 
second focus will be to identify the most cost-effective oste-
oporosis screening and treatment strategy in Australia, as 
has been performed in China.35
The model will be used to evaluate the costs and incre-
mental cost-effectiveness of alternative new interven-
tions for primary and/or secondary fracture prevention. 
Modelling is usually required in economic evaluations of 
therapies for osteoporosis fracture prevention, as most 
trials end before long-term outcomes are known.
Evaluating alternative management strategies will 
comprise the following steps:
i. Development of the scenario to be simulated. This 
involves choosing an intervention or management 
guideline for evaluation. Evidence must be available 
on its effect on fracture risks and synthesis undertak-
en to provide inputs for the simulation model. In the 
case of this analysis, the intervention to be evaluated 
may include denosumab, bisphosphonates and other 
commonly used medical treatments presently avail-
able to confirm cost-effectiveness, or to identify for 
disinvestment if no longer found to be cost-effective; 
and any new medications not yet reimbursed under 
the MBS.
ii. Simulating long-term outcomes and costs. This will 
involve carrying out two simulations: in the first, the 
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target population is assumed to receive standard of 
care and in the second, the target population is as-
sumed to receive standard of care plus the alternative 
treatment;
iii. Estimation of the incremental cost-effectiveness ratio. 
Results from the simulation model will be combined 
with other information (eg, the cost of treatment) in 
order to undertake an incremental cost-effectiveness 
analysis in which the net cost (ie, treatment costs mi-
nus savings due to fractures avoided) is divided by the 
net effectiveness (QALYs gained).
To ensure that the work undertaken has relevance to 
policy, we intend to hold a workshop on osteoporosis 
modelling in Australia during the course of this project. 
The aim of the workshop will be to obtain the opinions 
of key stakeholders (eg, officers from the Department 
of Health & Aging, representatives from Osteoporosis 
Australia (patients’ perspectives), clinicians from the 
Royal Australian College of General Practitioners and 
representatives from pharmaceutical companies) to assist 
in prioritising the work programme.
Model interface and availability
We will capitalise on our team member AJP’s extensive 
experience in his previous CORE Diabetes Model to 
ensure similar successful translation of the model into 
general use.36 A user-friendly graphical user interface will 
be developed, which will connect the user to the calcu-
lation engine and the results are generated. Input data, 
such as cohort characteristics, key cost and utility parame-
ters, and key treatment characteristics (costs and effects) 
will be accessible and editable by the user. They will be 
stored in a structured query language (SQL) database. 
Results generated by the model will also be written to and 
stored in a database for easy future access by the user. A 
user instruction manual and help files will be developed.
Like the CORE Diabetes Model, the osteoporosis model 
will be made available to university or other public sector 
research groups at no cost, while those seeking to use it 
for commercial use (eg, such as pharmaceutical compa-
nies preparing a regulatory submission) will pay a license 
fee that will support maintenance and further develop-
ment of the web-based model.
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